Get the Daily Brief
Latest Biotech News
Clinical readouts in oncology
Genentech disclosed head-to-head Phase 3 results showing its KRAS G12C inhibitor divarasib outperformed the approved KRAS G12C therapies in previously treated non-small-cell lung cancer. In the...
M&A and portfolio expansion in pharma
United Therapeutics moved into thymus-focused cell therapy by agreeing to acquire Thymmune Therapeutics for $140 million upfront, with up to $160 million in milestones. The deal centers on...
Large pharma deals in kidney disease R&D
AstraZeneca expanded its China collaboration with CSPC Pharmaceutical through a kidney drug discovery pact worth up to $1.7 billion. AstraZeneca will pay CSPC a $30 million upfront fee to jointly...
Regulatory and access milestones for advanced therapies
Otsuka reported new long-term kidney data intended to support Voyxact’s path from accelerated approval to full approval. The company said the Phase 3 study met its readout goal by stabilizing...
Genomics data infrastructure for clinical rare disease
A paper in Nature Medicine this week described Talos, an open-source automated genomic reanalysis tool designed to scale rare-disease diagnosis. Built by Australia’s Centre for Population Genomics...
Next-generation CRISPR control systems
Researchers led by Wang Yu at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences published dual small-molecule-controlled genome editing systems that keep CRISPR...
Protein degradation platform positioning
Arvinas CEO Randy Teel discussed what the company views as a major milestone for PROTACs and what comes next for the broader protein-degradation field. In an interview, Teel framed the modality’s...
Clinical-stage assays move into cancer ADC selection
One Biosciences is taking its single-cell molecular profiling platform into clinical studies for the first time, partnering with French company Adcytherix on an ADC development program. The effort...
Rare-disease funding momentum in pulmonary fibrosis
Celea Therapeutics, backed by PureTech, raised $180 million to advance deupirfenidone, its retooled pirfenidone program for idiopathic pulmonary fibrosis. The company said it will use the proceeds...
Energy-efficient pharma manufacturing at scale
Peptistar reported that it has integrated Asahi Kasei’s forward osmosis–membrane distillation (FO–MD) system into manufacturing-scale trial production for peptides and oligonucleotide active...
Regulatory milestone: first FDA-cleared neurostimulation option for PTSD
Neurovalens’ wearable neuromodulation device Modius Spero cleared a de novo path from the FDA, becoming the first approved neuromodulation technology for treating post-traumatic stress disorder...
Phase 3 pivot in KRAS G12C NSCLC: divarasib beats approved drugs head-to-head
Roche’s divarasib, a KRAS G12C inhibitor, produced superior outcomes in a Phase 3 head-to-head study (Krascendo 1) versus approved therapies in previously treated non-small-cell lung cancer...
Drug discovery deal: AstraZeneca expands kidney pipeline with CSPC collaboration
AstraZeneca entered a new kidney-focused drug discovery and development pact with CSPC Pharmaceutical, paying a $30 million upfront and agreeing to jointly discover and develop two kidney disease...
IPF funding jump: Celea raises $180M to push deupirfenidone into late-stage testing
Celea Therapeutics, a PureTech Health spinout focused on idiopathic pulmonary fibrosis (IPF), raised $180 million to advance deupirfenidone (a retooled version of pirfenidone/Esbriet) into...
M&A for rare-cell therapy: United Therapeutics buys Thymmune for $140M
United Therapeutics agreed to acquire Thymmune Therapeutics for $140 million upfront, with up to $160 million in milestones, betting on thymus-targeted regenerative cell therapy. Thymmune is...
Clinical pathway for gene editing safety: small-molecule switches control CRISPR activity in vivo
Researchers led by Dr. Wang Yu at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences reported drug-inducible control of CRISPR editing in living tissues using dual...
Transplant enabling research: perfusion device revives excised donor eyes for possible transplant vision
A research team led by Pia Cosma at the Centre for Genomic Regulation (Barcelona Institute of Science and Technology) developed the Eye-in-a-Care-Box (ECaBox), a perfusion device intended to...
Oncology assay leap: single-cell profiling platform moves into clinical trials with ADC partner Adcytherix
One Biosciences advanced its single-cell molecular profiling platform into clinical studies by partnering with French biotech Adcytherix on its lead ADC ADCX-020 for solid tumors. One Biosciences’...
Rare-disease enabling diagnostics: open-source genomic reanalysis tool Talos lands 241 diagnoses in study
An open-source automated genomic reanalysis tool called Talos delivered 241 rare-disease diagnoses in a recent Nature Medicine study after being tested on 4,735 previously unsolved patients’...
Biosafety research with direct translational readout: vascular organoid patches regenerate microvessels in pigs
Stanford University researchers reported that vascular organoid patches derived from human cells helped regenerate microvessels and improved heart function in pigs with ischemic heart disease. In...